FindTrial
Sign In

Effects of three-part manipulation on NEI network regulation in patients with chronic insomnia and LC-MS metabolomics study

Effect of Three-part Manipulation on NEI Network Regulation in Patients with Chronic Insomnia and LC-MS Metabolomics Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006726
Enrollment
Unknown
Registered
2022-10-31
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia

Interventions

control group:traditional regular tui na
treatment group:three-part manipulation group

Sponsors

The Third Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of CI and the diagnostic criteria of heart and spleen deficiency; 2.45 years old =65 years old, both genders; 3. Pittsburgh Sleep Index (PSQI) =7; 4. Hamilton Depression Scale 17-item version (HAMD-17) score =17; 5. Hamilton Anxiety Scale (HAMA) score =14; 6. Signed the informed consent and volunteered to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients with other types of sleep disorders such as respiratory related sleep disorder, restless legs syndrome, environmental sleep difficulties, sleep deprivation syndrome, short sleepers, etc. 2. The presence of other mental disorders, personality disorders and substance or substance abuse/dependence; 3. Patients with organic brain diseases and other physical diseases, progressive malignant tumors or other serious wasting diseases, and easy to be complicated with infection and bleeding; 4. Patients who have taken antidepressants, antipsychotics and sedative and hypnotic drugs in the past 2 weeks; 5. Massage treatment site of the skin infected or hypersensitive skin; 6. Pregnant and lactating women; 7. For other reasons, the investigator considers it inappropriate to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
liquid chromatography-mass spectrometry,LC-MS;Pittsburgh Sleep Quality Index, PSQI;—

Secondary

MeasureTime frame
Interleukin, IL-1;5-hydroxytryptamine;tumor necrosis factor, TNF;cortisol, CORT;glutamate, Glu;adrenocorticotrophic hormone, ACTH;?-aminobutyric acid, GABA;Fatigue Scale-14,FS-14;Insomnia Severity Index,ISI;Interleukin, IL-6;—

Countries

China

Contacts

Public ContactZhou Yunfeng

The Third Affiliated Hospital of Henan University of Chinese Medicine

zyf5680198@126.com13803846101

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026